Lunan Beite (鲁南贝特)鲁南贝特
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 鲁南贝特制药有限公司Chinese legal name: 鲁南贝特制药有限公司
主要成分Active Ingredients
- 氯唑沙宗Lvzuo Shazong
药物知识说明
氯唑沙宗是一种在国家药监局注册认定的药品。该药品含有氯唑沙宗-80dafa75等成分。
该药品关联的活性成分包括：氯唑沙宗Lvzuo Shazong。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：鲁南贝特制药有限公司Chinese legal name: 鲁南贝特制药有限公司。
您可以探索含有相同成分的其他药品：氯唑沙宗-80dafa75成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 鲁南贝特) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 氯唑沙宗Lvzuo Shazong.
Manufacturers recorded for this product: 鲁南贝特制药有限公司Chinese legal name: 鲁南贝特制药有限公司.
Explore other medicines containing the same ingredient: 氯唑沙宗 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 鲁南贝特Recorded Chinese name: 鲁南贝特
- 剂型Dosage form: 片剂Tablets
- 规格Specification: 每片含对乙酰氨基酚0.15g与氯唑沙宗0.125g。Recorded Chinese composition: 每片含对乙酰氨基酚0.15g与氯唑沙宗0.125g。
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 鲁南贝特制药有限公司Chinese legal name: 鲁南贝特制药有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20050180
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20050180
Manufacturer
Chinese legal name: 鲁南贝特制药有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20050180
生产企业
鲁南贝特制药有限公司(国产)
适应症
用于各种急性骨骼肌损伤。
用法用量
本品为分散片，使用时将其加入适量水中，搅拌均匀后服用，也可直接用水送服。每次2片，每日3～4次，疗程10天。
不良反应
偶见轻度的嗜睡、头晕、恶心、心悸、无力、上腹痛等反应，上述不良反应一般较轻微，可自行消失或停药后缓解。
禁忌
对本品成份过敏者禁用。
注意事项
肝、肾功能损害者慎用。
贮藏
遮光、密闭、室温（10～30℃）干燥处保存。
规格
每片含对乙酰氨基酚0.15g与氯唑沙宗0.125g。
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.